To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.
Current Funding Opportunities:
NEW! MNDA PhD StudentshipSponsor: Motor Neurone Disease Association
Description: Applications are invited from prospective supervisors, based in laboratories in the UK and Ireland, for studentships to be funded from autumn 2018. Awards will be offered for three years. The Association will provide: a student stipend of £16,000 per annum (£17,000 in London) which will be increased by £500 increments for the following two years; £8,000 per annum for laboratory expenses; and a total budget of £1,000, over three years, for conference attendance.
Deadline: Summary application due by April 28, 2017.
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by June 1, 2017.
Identify and Characterize Potential Environmental Risk Factors for ALS and Evaluate Their Impact on ALS Disease Incidence and ProgressionSponsor: Centers for Disease Control and Prevention
Description: The ATSDR is soliciting investigator-initiated research that will identify and characterize environmental toxicants in human biological samples that may be potential environmental risk factors for ALS. Applications are also sought that will evaluate the impact of environmental toxicants on the development and progression of ALS, including gene-environment interactions. The award is $350,000 to $500,000 USD.
Deadline: Application due by March 31, 2017.
Description: Provides funding (maximum of $1,500,000 over up to 3 years) for high-potential translational research projects with excellent preliminary data that will advance the development of therapeutics for neurodegenerative diseases of aging including frontotemporal dementia. Projects include the development of a therapeutic and/or a tool that helps to accelerate the development of therapies for these diseases. Research must take place at institutions that are Canada Revenue Agency qualified donees located in Canada. If your project is awarded, funds are provided in tranches when experimental milestones are successfully completed.
Deadline: Letter of Intent due by March 31, 2017.
Description: This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.
Deadline: Application due by April 4, 2017.
Description: The objective of this initiative is accelerate completion of translational stage activities necessary for advancement to clinical study or broad end use for any one of the following stem cell product types: (1) stem cell-based therapeutic candidate; (2) diagnostic based on stem cells, or critical for stem cell based therapy development or use; (3) medical device (non-diagnostic) for a stem cell-based therapy or critical for stem cell based therapy development or use; (4) novel tool that addresses a critical bottleneck to the discovery or development of stem cell-based therapy. A maximum of $1M to $4M USD will be awarded for 24 to 30 months depending on the type of stem cell-based strategy being developed. Research must take place at a California institution.
Deadline: Application due by April 5, 2017.
Description: The CReATe Consortium, an NIH-funded Rare Diseases Clinical Research Consortium (RDCRC), in partnership with the ALS Association, is pleased to announce this request for applications (RFA) to support the discovery and/or validation of biomarkers that are relevant to the development of therapies for patients with ALS or a related disorder (including primary lateral sclerosis [PLS], hereditary spastic paraplegia [HSP], progressive muscular atrophy [PMA], multisystem proteinopathy [MSP], and frontotemporal dementia [FTD]). Proposals to develop either wet(e.g. biological-fluid based) or dry (e.g.neuroimaging, neurophysiological) biomarkers are encouraged. Investigators submitting an application in response to this RFA may also request to use the data and/or biological samples collected by the CReATe Consortium. A maximum of $60,000 in total costs for a maximum period of one year may be requested.
Deadline: Letter of Intent due by April 7, 2017.
Description: The aim of this research should be to apply genomics and/or other –omics and/or other high-throughput approaches for the molecular characterisation of rare diseases in view of developing molecular diagnoses for a large number of undiagnosed rare diseases. Expected Impact: Providing better and faster means of high quality and clinical utility for the correct diagnosis of undiagnosed rare diseases for which there is no or unsatisfactory diagnosis available. Outside of EU or associated countries? Check the program link to see if funds are available.
Deadline: Application due by April 11, 2017.
Description: The Weston Brain Institute Postdoctoral Scholars program supports top-tier Canadian postdoctoral scholars by providing international training at the University of Oxford and affiliation with Merton College. Proposed work in the Institute’s area of focus, translational research to accelerate the development of therapeutics for neurodegenerative diseases of aging including FTD. Prior to submitting an application, candidates should independently identify a host lab and potential supervisor at the University of Oxford who agrees to supervise them if awarded. Awardees will receive salary support for their postdoctoral positions at Oxford. The fellowship will be £57,000 per year (£44,000 per year + benefits) for 2 years.
Deadline: Application due by April 11, 2017.
Description: The purpose of this grant program is nurture promising young investigators into a career focused on ALS research. A Clinical Research Fellowship would be funded at $100,000 CAD per year for up to two years. Each Postdoctoral Fellowship would be funded at $55,000 CAD per year for up to three years. Each Doctoral Award would be funded at $25,000 CAD per year for up to three years. Non-Canadians training in Canadian labs are eligible to apply for doctoral and postdoctoral fellowships.
Deadline: Application due by April 14, 2017.
Description: The UK: Novel Biomarkers program was launched to support high-risk, high-reward, translational research on novel biomarkers of neurodegenerative diseases of aging including frontotemporal dementia. The program funds testing of novel biomarkers in clinical samples/data or patients to accelerate the development of therapeutics for these diseases. Up to £333,000 over up to 3 years is available per project. Funds are provided contingent on meeting milestones. If your project is awarded, funds are provided in tranches when experimental milestones are successfully completed.
Deadline: Letter of Intent due by April 19, 2017.
Description: This call supports research aimed at improving the lives of people living with ALS and their families. The proposed studies are expected to generate data that can be implemented in ALS clinical centres. This includes: (1) gaps in delivery of care; (2) nutritional, psychological or respiratory interventions; (3) assistive technologies (AAC); (4) telemedicine; (5) novel endpoints for clinical trials. Studies will also be supported that address the needs of caregivers of patients with ALS with behavioral/cognitive challenges. The maximum award is $100,000 per year for up to 2 years. Applicants must clearly and explicitly articulate what impact the project may have on the quality of life for people with ALS. Clinical trials will not be supported with this funding opportunity.
Deadline: Study Outline due by April 22, 2017.
Description: This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.
Deadline: Application due by May 18, 2017.
Description: The ALS Association’s TREAT ALS™ program funds research from early target identification to preclinical research and early pilot clinical trials. As part of the program, The Association is requesting letters of intent for its drug development contract program, milestone driven research to develop new treatments for ALS. This call supports the preclinical assessment of therapeutics for ALS. The proposed studies are expected to be product-driven and focused on therapeutics. It is anticipated that the agents and/or data generated from these awards will lead to the advancement of new therapies for ALS. The program compliments the Department of Defense ALS research program and the translational programs at the National Institutes of Health and specifically aims to support studies that will de-risk and incentive industry partners to further pursue interesting targets. The maximum award is $200,000 USD for 2 years. Letters of intent can be submitted to the ALS association beginning on April 22, 2017.
Deadline: Letter of Intent due by May 23, 2017.
Description: The purpose of the program is to invest in the best possible projects in Canada that are i) novel research approaches, supported by sound rationale and a feasible experimental plan, but not necessarily preliminary data, ii) part of an ongoing ALS research program, and aimed toward the vision of ALS Canada that “By 2024, ALS is a treatable, not terminal disease” or iii) research focused on avenues to maximize function, minimize disability and optimize quality of life through symptom management, and support to families and persons or families living with ALS. Examples include, but are not limited to, management of secretions and cramps, psychological interventions to address mental health issues, nutritional interventions, respiratory care, engineering applications to reduce physical limitations, and programs to address the needs of caregivers. Up to eight awards of up to $125,000 CAD will be awarded for a duration 1-2 years.
Deadline: Application due by June 3, 2017.
Description: Applications should focus on accelerating therapy development in neuromuscular diseases. The diseases funded include ALS. Such projects may include: (1) new target identification; (2) target validation; (3) screening for new therapeutic molecules that hit validated targets and (4) addressing a need in the field (e.g., developing a novel animal or cell model of the disease or developing new technologies). The award is $100,000 per year for 1 to 3 years.
Deadline: Letter of Intent due by June 15, 2017.
Description: These grants support research that is aimed at discovering the causes of and finding a cure for ALS. The Foundation funds research that is innovative and aggressive. The research must be of high scientific merit. We encourage partnerships and collaborative efforts in proposing initiatives to fill gaps not currently being investigated and that involve novel approaches. The foundation will begin receiving applications in March 2017.
Deadline: Application due by August 11, 2017.
Description: The aim of the Foundation is to encourage basic biomedical research related to understanding the cause of ALS. The funding is 100,000 CHF over 2 years.
Deadline: Application due by September 30, 2017.
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Applications for project grants should not exceed £85,000 per annum (and £255,000 in total) without the prior agreement of the MND Association. Applications received beginning September 8, 2017.
Deadline: Application due by November 3, 2017.
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.
Description: MNDA invests in research that fills knowledge gaps in clinical management of MND, adding to the evidence base and driving improvements in quality of care for people affected by MND.
Deadline: Now accepting applications.
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.
This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.
Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.
Deadline: Now accepting rolling applications.